Formulary Monographs [EMPAGLIFLOZIN, 682018]
|
|
EMPAGLIFLOZIN
|
|
|
|
|
|
SODIUM-GLUCOSE COTRANSPORTER INHIBITOR
|
|
|
Monotherapy or with other antidiabetic medications, including insulin, in the management of type 2 diabetes mellitus; To reduce the risk of cardiovascular death in those with type 2 diabetes mellitus and established cardiovascular disease.
|
|
|
Urinary tract infection, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, female genital mycotic infections, male genital mycotic infections, and nausea
|
|
|
The usual oral dose of empagliflozin is 10 mg once daily, which may be increased to 25 mg daily, if necessary. When given with metformin, empagliflozin may be given in 2 divided doses. Doses of insulin, sulfonylurea, or other insulin secretagogues may nee
|
|
|
|
|
|
|
|
|
|
|
|
|